Literature DB >> 6408173

B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.

L M Nadler, K C Anderson, G Marti, M Bates, E Park, J F Daley, S F Schlossman.   

Abstract

The characterization of a new B cell-specific antigen (B4) is described in this report. With the use of a monoclonal antibody to B4, it was shown that B4 is present on B cells isolated from peripheral blood and lymphoid organs, on cell lines derived from normal and malignant B cells, and on tumor cells isolated from patients with B cell-derived neoplasms. B4, in contrast, was not detected on normal, activated, or malignant cells of T or myeloid origin. The B4 antigen is distinct from known B cell antigens, including sIg, Ia, B1, B2, Fc, and C3. Examination of mitogen-stimulated B lymphocytes suggests that the B4 antigen initially increases with B cell activation and then is lost at the terminal stage of B cell differentiation. Moreover, the observation that B4 is expressed on almost all early B cell tumors suggests that it may precede B1, CALLA, cytoplasmic mu, and B2 in early B cell ontogeny.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6408173

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  100 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  B lymphocyte-restricted expression of prion protein does not enable prion replication in prion protein knockout mice.

Authors:  F Montrasio; A Cozzio; E Flechsig; D Rossi; M A Klein; T Rülicke; A J Raeber; C A Vosshenrich; J Proft; A Aguzzi; C Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP.

Authors:  Z Kozmik; S Wang; P Dörfler; B Adams; M Busslinger
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

4.  Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes.

Authors:  L J Zhou; D C Ord; S A Omori; T F Tedder
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

5.  Treatment of advanced leukemia in mice with mRNA engineered T cells.

Authors:  David M Barrett; Yangbing Zhao; Xiaojun Liu; Shuguang Jiang; Carmine Carpenito; Michael Kalos; Richard G Carroll; Carl H June; Stephan A Grupp
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

6.  Simplified process for the production of anti-CD19-CAR-engineered T cells.

Authors:  Barbara Tumaini; Daniel W Lee; Tasha Lin; Luciano Castiello; David F Stroncek; Crystal Mackall; Alan Wayne; Marianna Sabatino
Journal:  Cytotherapy       Date:  2013-08-28       Impact factor: 5.414

Review 7.  Blinatumomab for the treatment of acute lymphoblastic leukemia.

Authors:  Jason B Kaplan; Marina Grischenko; Francis J Giles
Journal:  Invest New Drugs       Date:  2015-09-17       Impact factor: 3.850

8.  Lymphocyte compartments in human spleen. An immunohistologic study in normal spleens and uninvolved spleens in Hodgkin's disease.

Authors:  W Timens; S Poppema
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

9.  Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.

Authors:  Shigui Zhu; Benoit J Van den Eynde; Pierre G Coulie; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

10.  In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.

Authors:  G A Pietersz; L Wenjun; V R Sutton; J Burgess; I F McKenzie; H Zola; J A Trapani
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.